Aarti Pharmalabs Q3 FY25 results (Oct–Dec 2024) and concall

Aarti Pharmalabs reported a record-breaking Q3 FY25, with consolidated revenue, EBITDA, and PAT growing significantly by 20%, 34%, and 40% YoY respectively. All three segments – Xanthine derivatives, API Intermediates, and CDMO/CMO – performed well. While facing headwinds from Chinese competition and minor delays in the Atali project, the company remains optimistic about exceeding its FY25 EBITDA growth guidance and delivering significant long-term growth, particularly in CDMO.